We then demonstrate in a mouse model of mesothelioma that the combination of anti-PD-1 and anti-TIGIT elicits an enhanced anti-tumour response compared to clinical standard-of-care therapies (anti-PD-1 + CTLA-4 combination and chemotherapy). This evidence concerns the gene CTLA4 and neoplasm.